Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass

被引：2

作者：

Duffield, Amy S. ^{[1
,2
,4
]}

Webster, Jonathan ^{[2
]}

Smith, B. Douglas ^{[2
]}

Necciai, Julius S. ^{[3
]}

McCuiston, Austin ^{[1
,5
]}

Ware, Alisha D. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Hematol Pathol, 401 N Broadway,Pathol Weinberg Bldg,Suite 2242, Baltimore, MD 21231 USA

[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Div Hematol Malignancies, Baltimore, MD USA

[3] Dent Ctr, Mt Airy, MD USA

[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, Div Hematopathol, 1275 York Ave, New York, NY 10065 USA

[5] Murray Calloway Cty Hosp, Dept Pathol, 803 Popular St, Murray, KY 42071 USA

来源：

HEAD & NECK PATHOLOGY | 2021年 / 15卷 / 04期

基金：

美国国家卫生研究院;

关键词：

Eosinophilia; Mastocytosis; PDGFRA-associated myeloproliferative neoplasm; Gingiva; Oral pathology; Tyrosine kinase inhibitor;

D O I：

10.1007/s12105-021-01305-9

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Myeloid neoplasms with PDGFRA rearrangement are rare, and most commonly present with features of chronic eosinophilic leukemia; however, they rarely manifest as acute myeloid or lymphoblastic leukemia. Patients typically present with symptoms of hypereosinophilia including cardiovascular and pulmonary symptoms. An increase in mast cells is also a common feature of this disease, and there may be elevated serum tryptase with significant clinical overlap with systemic mastocytosis. Here, we present an unusual case of a myeloid neoplasm with PDGFRA rearrangement manifesting as a retromolar pad mass in a patient with a prior diagnosis of systemic mastocytosis. This case highlights the possibility of soft tissue involvement by myeloid neoplasms with PDGFRA rearrangement in the oral cavity. The identification of this entity is of significant clinical importance because many patients can be effectively treated with tyrosine kinase inhibitors.

引用

页码：1399 / 1403

页数：5

共 18 条

[1] The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study [J].

Baccarani, Michele ;

Cilloni, Daniela ;

Rondoni, Michela ;

Ottaviani, Emanuela ;

Messa, Francesca ;

Merante, Serena ;

Tiribelli, Mario ;

Buccisano, Francesco ;

Testoni, Nicoletta ;

Gottardi, Enrico ;

de Vivo, Antonio ;

Giugliano, Emilia ;

Iacobucci, Ilaria ;

Paolini, Stefania ;

Soverini, Simona ;

Rosti, Gianantonio ;

Rancati, Francesca ;

Astolfi, Cinzia ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Martinelli, Giovanni .

HAEMATOLOGICA, 2007, 92 (09) :1173-1179

[2] Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[3] Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome [J].

Bain, Barbara J. ;

Fletcher, Sarah H. .

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2007, 27 (03) :377-+

[4] A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].

Cools, J ;

DeAngelo, DJ ;

Gotlib, J ;

Stover, EH ;

Legare, RD ;

Cortes, J ;

Kutok, J ;

Clark, J ;

Galinsky, I ;

Griffin, JD ;

Cross, NCP ;

Tefferi, A ;

Malone, J ;

Alam, R ;

Schrier, SL ;

Schmid, J ;

Rose, M ;

Vandenberghe, P ;

Verhoef, G ;

Boogaerts, M ;

Wlodarska, I ;

Kantarjian, H ;

Marynen, P ;

Coutre, SE ;

Stone, R ;

Gilliland, DG .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214

[5] Immunohistochemical Study of Calretinin in Normal Skin and Cutaneous Adnexal Proliferations [J].

Gonzalez-Guerra, Elena ;

Kutzner, Heinz ;

Rutten, Arno ;

Requena, Luis .

AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2012, 34 (05) :491-505

[6] Cessation of imatinib mesylate may lead to sustained hematologic and mole remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome [J].

Helbig, Grzegorz ;

Kyrcz-Krzemien, Slawomira .

AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (01) :115-115

[7] Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia:: implications for optimal dosing [J].

Klion, Amy D. ;

Robyn, Jamie ;

Maric, Irina ;

Fu, Weiming ;

Schmid, Laura ;

Lemery, Steven ;

Noel, Pierre ;

Law, Melissa A. ;

Hartsell, Marilyn ;

Talar-Williams, Cheryl ;

Fay, Michael P. ;

Dunbar, Cynthia E. ;

Nutman, Thomas B. .

BLOOD, 2007, 110 (10) :3552-3556

[8] How I treat hypereosinophilic syndromes [J].

Klion, Amy D. .

BLOOD, 2015, 126 (09) :1069-1077

[9] FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib [J].

Lierman, E. ;

Michaux, L. ;

Beullens, E. ;

Pierre, P. ;

Marynen, P. ;

Cools, J. ;

Vandenberghe, P. .

LEUKEMIA, 2009, 23 (05) :845-851

[10] Diagnostic value of calretinin in mast cell lesions of the skin [J].

Mangini, J ;

Silverman, JF ;

Dabbs, DJ ;

Tung, MY ;

Silverman, AR .

INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2000, 8 (02) :119-122

← 1 2 →